Envoy Medical (COCH) announces a peer-reviewed publication in Otology & Neurotology, discussing early experiences with and highlighting potential benefits of the Company’s investigational fully implanted Acclaim Cochlear Implant, Acclaim CI. The paper, titled, “Early Hearing Outcomes and Audiological Experiences with a Novel Fully Implanted Cochlear Implant,” discusses the initial results from a first-in-human, early feasibility study. The study had only been active for six months at the time these data being reported were collected and analyzed. All three patients are now approaching two years with their implants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COCH:
- Envoy Medical receives European patent for modular cochlear implant
- Envoy Medical receives FDA approval to initiate study for hearing device
- Envoy Medical supports ITEM Coalition letter to CMS on hearing devices
- Envoy Medical announces AMA CPT Editorial Panel approved codes for AMEI
- Envoy Medical initiated with a Buy at Brookline